Moreover, it is worth noting that the inhibition of RRM2 has consistently demonstrated its ability to induce cell cycle arrest and promote apoptosis in cancer cells, thereby firmly establishing RRM2 as a highly promising therapeutic target [31-34] Additionally, the expression levels of RRM2 have emerged as valuable prognostic markers in numerous cancer types, underscoring their potential utility in predicting disease outcomes and guiding treatment decisions [35-37]. Here, RRM2 is linked to cancer.